Department of Ophthalmology, University of Cologne, D-50931 Cologne, Germany.
J Neuroinflammation. 2014 Jan 8;11:3. doi: 10.1186/1742-2094-11-3.
The translocator protein (18 kDa) (TSPO) is a mitochondrial protein expressed on reactive glial cells and a biomarker for gliosis in the brain. TSPO ligands have been shown to reduce neuroinflammation in several mouse models of neurodegeneration. Here, we analyzed TSPO expression in mouse and human retinal microglia and studied the effects of the TSPO ligand XBD173 on microglial functions.
TSPO protein analyses were performed in retinoschisin-deficient mouse retinas and human retinas. Lipopolysaccharide (LPS)-challenged BV-2 microglial cells were treated with XBD173 and TSPO shRNAs in vitro and pro-inflammatory markers were determined by qRT-PCR. The migration potential of microglia was determined with wound healing assays and the proliferation was studied with Fluorescence Activated Cell Sorting (FACS) analysis. Microglial neurotoxicity was estimated by nitrite measurement and quantification of caspase 3/7 levels in 661 W photoreceptors cultured in the presence of microglia-conditioned medium. The effects of XBD173 on filopodia formation and phagocytosis were analyzed in BV-2 cells and human induced pluripotent stem (iPS) cell-derived microglia (iPSdM). The morphology of microglia was quantified in mouse retinal explants treated with XBD173.
TSPO was strongly up-regulated in microglial cells of the dystrophic mouse retina and also co-localized with microglia in human retinas. Constitutive TSPO expression was high in the early postnatal Day 3 mouse retina and declined to low levels in the adult tissue. TSPO mRNA and protein were also strongly induced in LPS-challenged BV-2 microglia while the TSPO ligand XBD173 efficiently suppressed transcription of the pro-inflammatory marker genes chemokine (C-C motif) ligand 2 (CCL2), interleukin 6 (IL6) and inducible nitric oxide (NO)-synthase (iNOS). Moreover, treatment with XBD173 significantly reduced the migratory capacity and proliferation of microglia, their level of NO secretion and their neurotoxic activity on 661 W photoreceptor cells. Furthermore, XBD173 treatment of murine and human microglial cells promoted the formation of filopodia and increased their phagocytic capacity to ingest latex beads or photoreceptor debris. Finally, treatment with XBD173 reversed the amoeboid alerted phenotype of microglial cells in explanted organotypic mouse retinal cultures after challenge with LPS.
These findings suggest that TSPO is highly expressed in reactive retinal microglia and a promising target to control microglial reactivity during retinal degeneration.
转位蛋白(18 kDa)(TSPO)是一种在反应性神经胶质细胞上表达的线粒体蛋白,也是大脑神经胶质增生的生物标志物。已经证明 TSPO 配体可减少几种神经退行性变小鼠模型中的神经炎症。在这里,我们分析了 TSPO 在小鼠和人视网膜小胶质细胞中的表达,并研究了 TSPO 配体 XBD173 对小胶质细胞功能的影响。
在视网膜视蛋白缺失的小鼠视网膜和人视网膜中进行 TSPO 蛋白分析。用脂多糖(LPS)处理 BV-2 小胶质细胞,并用 XBD173 和 TSPO shRNA 体外处理,并通过 qRT-PCR 测定促炎标志物。用划痕愈合实验测定小胶质细胞的迁移潜力,用荧光激活细胞分选(FACS)分析研究细胞增殖。通过在存在小胶质细胞条件培养基的情况下培养 661W 光感受器来估计小胶质细胞的神经毒性,并测量亚硝酸盐水平和半胱天冬酶 3/7 水平的定量。在 BV-2 细胞和人诱导多能干细胞(iPS)衍生的小胶质细胞(iPSdM)中分析 XBD173 对丝状伪足形成和吞噬作用的影响。用 XBD173 处理小鼠视网膜外植体后,定量小胶质细胞的形态。
TSPO 在营养不良的小鼠视网膜的小胶质细胞中强烈上调,并且在人视网膜中也与小胶质细胞共定位。在出生后第 3 天的早期小鼠视网膜中,TSPO 的组成型表达水平较高,而在成年组织中则下降至低水平。LPS 刺激的 BV-2 小胶质细胞中 TSPO mRNA 和蛋白也强烈诱导,而 TSPO 配体 XBD173 可有效抑制趋化因子(C-C 基序)配体 2(CCL2)、白细胞介素 6(IL6)和诱导型一氧化氮(NO)合酶(iNOS)的促炎标志物基因的转录。此外,XBD173 处理可显著降低小胶质细胞的迁移能力和增殖能力、NO 分泌水平以及对 661W 光感受器细胞的神经毒性活性。此外,XBD173 处理可促进鼠源和人源小胶质细胞丝状伪足的形成,并增加其吞噬乳胶珠或光感受器碎片的能力。最后,用 XBD173 处理 LPS 刺激的离体器官型小鼠视网膜培养物中的小胶质细胞,可逆转其阿米巴样激活表型。
这些发现表明,TSPO 在反应性视网膜小胶质细胞中高度表达,是控制视网膜变性过程中小胶质细胞反应的有希望的靶点。